

Literatura

1. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. *Hematology Am Soc Hematol Educ Program* 2011; 2011(1): 498–505.
2. Crump M, Neelapu SS, Faraoo U et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood* 2017; 130(16): 1800–1808.
3. Polgárová K, Trněný M. Imunoterapie v léčbě lymfomů. *Postgraduální medicína* 2020; 22(1): 9–18.
4. Agresivní lymfomy. In: Belada D, Trněný M (editoři). *Diagnostické a léčebné postupy u nemocných s lymfomy*, XI. vydání. KAP CZ Brno 2020: 97–102.
5. Ross J, Carver ML. MediaKite announces Yescarta® CAR T-cell therapy improved event-free survival by 60% over chemotherapy plus stem cell transplant in second-line relapsed or refractory large B-cell lymphoma [online]. 2021 [cit. 2021-10-11]. Dostupné z: <https://www.businesswire.com/news/home/20210628005449/en/>
6. Lee DW, Santomasso BD, Locke FL et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant* 2019; 25: 625–638.
7. Yakoub-Agha I, Chabannon C, Bader P et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the Joint accreditation committee of ISCT and EBMT (JACIE). *Haematologica* 2020; 105(2): 297–316.
8. Yescarta, Souhrn údajů o přípravku, verze z 22. 6. 2020.
9. Neelapu SS, Locke FL, Bartlett NL et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med* 2017; 377: 2531–2544.
10. Locke FL, Ghobadi A, Jacobson CA et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. *Lancet Oncol* 2019; 20: 31–42.
11. Jacobson C, Chavez JC, Sehgal AR et al. Primary analysis of Zuma-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). *Blood* 2020; 136(Supplement 1): 40–41.
12. Jacobson CA, Westin JR, Miklos DB et al. Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL). *Cancer Res* 2020; 80(16 Suppl): Abstract nr CT055.
13. Oluwole OO, Bishop MR, Gisselbrecht C et al. ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). *J Clin Oncol* 2018; 36(15_suppl): TPS7585.
14. Jacobson CA, Locke FL, Miklos DB et al. Outcomes of patients (Pts) in ZUMA-9, a multicenter, open-label study of axicabtagene ciloleucel (Axi-cel) in relapsed/refractory large B cell lymphoma (R/R LBCL) for expanded access and commercial out-of-specification (OOS) product. *Blood* 2020; 136(Supplement 1): 2–3.
15. Reshef R, Miklos DB, Timmerman JM et al. ZUMA-11: A phase 1/2 multicenter study of axicabtagene ciloleucel (Axi-cel) + utomilumab patients with refractory large B cell lymphoma. *Blood* 2019; 134(Supplement_1): 4084.
16. Neelapu SS, Dickinson M, Urickson ML et al. Interim Analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (Axi-cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). *Blood* 2020; 136(Supplement 1): 49.
17. Neelapu SS, Kharfan-Dabaja MA, Oluwole OO et al. A phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory large B-cell lymphoma (ZUMA-14). *Blood* 2019; 134(Supplement_1): 4093.
18. Catlett G, Lada A. Humanigen reports positive data with lenzilumab in the ZUMA-19 CAR-T phase 1 b study in DLBCL and plans to initiate a potential registrational study [online]. 2021 [cit. 2021-10-11]. Dostupné z: <https://www.businesswire.com/news/home/20210419005250/en/>
19. Jacobson CA, Hunter B, Armand P et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. *Blood* 2018; 132(Supplement 1): 92.
20. Jacobson CA, Hunter BR, Redd R et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. *J Clin Oncol* 2020; 38: 3095–3106.
21. Nastoupil LJ, Jain MD, Feng L et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. *J Clin Oncol* 2020; 38: 3119–3128.
22. Vercellino L, Di Blasi R, Kanoun S et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv* 2020; 4(22): 5607–5615.
23. Bethge WA, Holtick U, Wagner-Drouet EM, et al. Standard-of-care CAR-T cell therapy for large B-cell lymphoma: real world data Germany. EBMT annual meeting 2021, abstract AA2–2.
24. Folber F. Update ZUMA-1 (4leté sledování) a dlouhodobé zkušenosti s léčbou přípravkem Yescarta v ČR a v zahraničí. II. Český hematologický a transfuziologický sjezd, 13. 9. 2021, Olomouc.
25. Wang M, Munoz J, Goy A et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med* 2020; 382: 1331–1342.
26. Shah BD, Bishop MR, Oluwole OO et al. End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). *J Clin Oncol* 2019; 37(15_suppl): 7006.